Serum GADD45a methylation is a useful biomarker to distinguish benign vs malignant prostate disease

Isildinha Reis, K. Ramachandran, C. Speer, E. Gordian, Rakesh Singal

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Prostate-specific antigen (PSA) screening for prostate cancer results in a large number of unnecessary prostate biopsies. There is a need for specific molecular markers that can be used in combination with PSA to improve the specificity of PSA screening. We examined GADD45a methylation in blood DNA as a molecular marker for prostate cancer diagnosis.Methods: The study included 82 men, with PSA levels >4 ng ml-1 and/or abnormal digital rectal exam, who underwent prostate biopsy. We compared GADD45a methylation in DNA from serum and buffy coat in 44 patients (22 prostate cancer and 22 benign). GADD45a methylation in serum DNA was examined in 82 patients (34 cancer and 48 benign).Results: There was no significant difference in buffy coat GADD45a methylation between cancer and benign patients. Serum GADD45a methylation was significantly higher in cancer than in benign patients. Classification and regression tree predictive model for prostate cancer including risk groups defined by PSA, free circulating DNA (fcDNA) level and GADD45a methylation yielded specificity of 87.5%, sensitivity of 94.1% and receiver operator characteristic curve area of 0.937.Conclusions: Serum GADD45a methylation in combination with PSA and fcDNA level was useful in distinguishing benign from prostate cancer patients.

Original languageEnglish (US)
Pages (from-to)460-468
Number of pages9
JournalBritish Journal of Cancer
Volume113
Issue number3
DOIs
StatePublished - Jul 28 2015

Fingerprint

Prostate-Specific Antigen
Methylation
Prostate
Biomarkers
Prostatic Neoplasms
Serum
DNA
Biopsy
Neoplasms
DNA Methylation
Sensitivity and Specificity

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Serum GADD45a methylation is a useful biomarker to distinguish benign vs malignant prostate disease. / Reis, Isildinha; Ramachandran, K.; Speer, C.; Gordian, E.; Singal, Rakesh.

In: British Journal of Cancer, Vol. 113, No. 3, 28.07.2015, p. 460-468.

Research output: Contribution to journalArticle

@article{29eb4428e89f46b3a6dc9557ae47e030,
title = "Serum GADD45a methylation is a useful biomarker to distinguish benign vs malignant prostate disease",
abstract = "Background: Prostate-specific antigen (PSA) screening for prostate cancer results in a large number of unnecessary prostate biopsies. There is a need for specific molecular markers that can be used in combination with PSA to improve the specificity of PSA screening. We examined GADD45a methylation in blood DNA as a molecular marker for prostate cancer diagnosis.Methods: The study included 82 men, with PSA levels >4 ng ml-1 and/or abnormal digital rectal exam, who underwent prostate biopsy. We compared GADD45a methylation in DNA from serum and buffy coat in 44 patients (22 prostate cancer and 22 benign). GADD45a methylation in serum DNA was examined in 82 patients (34 cancer and 48 benign).Results: There was no significant difference in buffy coat GADD45a methylation between cancer and benign patients. Serum GADD45a methylation was significantly higher in cancer than in benign patients. Classification and regression tree predictive model for prostate cancer including risk groups defined by PSA, free circulating DNA (fcDNA) level and GADD45a methylation yielded specificity of 87.5{\%}, sensitivity of 94.1{\%} and receiver operator characteristic curve area of 0.937.Conclusions: Serum GADD45a methylation in combination with PSA and fcDNA level was useful in distinguishing benign from prostate cancer patients.",
author = "Isildinha Reis and K. Ramachandran and C. Speer and E. Gordian and Rakesh Singal",
year = "2015",
month = "7",
day = "28",
doi = "10.1038/bjc.2015.240",
language = "English (US)",
volume = "113",
pages = "460--468",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Serum GADD45a methylation is a useful biomarker to distinguish benign vs malignant prostate disease

AU - Reis, Isildinha

AU - Ramachandran, K.

AU - Speer, C.

AU - Gordian, E.

AU - Singal, Rakesh

PY - 2015/7/28

Y1 - 2015/7/28

N2 - Background: Prostate-specific antigen (PSA) screening for prostate cancer results in a large number of unnecessary prostate biopsies. There is a need for specific molecular markers that can be used in combination with PSA to improve the specificity of PSA screening. We examined GADD45a methylation in blood DNA as a molecular marker for prostate cancer diagnosis.Methods: The study included 82 men, with PSA levels >4 ng ml-1 and/or abnormal digital rectal exam, who underwent prostate biopsy. We compared GADD45a methylation in DNA from serum and buffy coat in 44 patients (22 prostate cancer and 22 benign). GADD45a methylation in serum DNA was examined in 82 patients (34 cancer and 48 benign).Results: There was no significant difference in buffy coat GADD45a methylation between cancer and benign patients. Serum GADD45a methylation was significantly higher in cancer than in benign patients. Classification and regression tree predictive model for prostate cancer including risk groups defined by PSA, free circulating DNA (fcDNA) level and GADD45a methylation yielded specificity of 87.5%, sensitivity of 94.1% and receiver operator characteristic curve area of 0.937.Conclusions: Serum GADD45a methylation in combination with PSA and fcDNA level was useful in distinguishing benign from prostate cancer patients.

AB - Background: Prostate-specific antigen (PSA) screening for prostate cancer results in a large number of unnecessary prostate biopsies. There is a need for specific molecular markers that can be used in combination with PSA to improve the specificity of PSA screening. We examined GADD45a methylation in blood DNA as a molecular marker for prostate cancer diagnosis.Methods: The study included 82 men, with PSA levels >4 ng ml-1 and/or abnormal digital rectal exam, who underwent prostate biopsy. We compared GADD45a methylation in DNA from serum and buffy coat in 44 patients (22 prostate cancer and 22 benign). GADD45a methylation in serum DNA was examined in 82 patients (34 cancer and 48 benign).Results: There was no significant difference in buffy coat GADD45a methylation between cancer and benign patients. Serum GADD45a methylation was significantly higher in cancer than in benign patients. Classification and regression tree predictive model for prostate cancer including risk groups defined by PSA, free circulating DNA (fcDNA) level and GADD45a methylation yielded specificity of 87.5%, sensitivity of 94.1% and receiver operator characteristic curve area of 0.937.Conclusions: Serum GADD45a methylation in combination with PSA and fcDNA level was useful in distinguishing benign from prostate cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=84938409095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938409095&partnerID=8YFLogxK

U2 - 10.1038/bjc.2015.240

DO - 10.1038/bjc.2015.240

M3 - Article

C2 - 26171936

AN - SCOPUS:84938409095

VL - 113

SP - 460

EP - 468

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 3

ER -